Provided by Tiger Trade Technology Pte. Ltd.

CRISPR Therapeutics AG

46.00
+1.663.74%
Volume:677.99K
Turnover:31.09M
Market Cap:4.42B
PE:-7.11
High:46.35
Open:44.91
Low:44.91
Close:44.34
52wk High:78.48
52wk Low:30.04
Shares:95.99M
Float Shares:90.53M
Volume Ratio:1.07
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4700
EPS(LYR):-6.4700
ROE:-30.18%
ROA:-15.76%
PB:2.30
PE(LYR):-7.11

Loading ...

Intellia Therapeutics Eyes 2026 Pivotal CRISPR Milestone

TIPRANKS
·
Feb 28

Why Is CRISPR Therapeutics Stock Surging Thursday?

Benzinga
·
Feb 27

Is CRISPR Therapeutics (CRSP) Attractively Priced After Mixed Long Term Share Performance?

Simply Wall St.
·
Feb 26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON)

TIPRANKS
·
Feb 16

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

Benzinga
·
Feb 14

Evercore ISI Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Feb 13

Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital

TIPRANKS
·
Feb 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 13

CRISPR Therapeutics Ag : TD Cowen Raises Target Price to $45 From $40

THOMSON REUTERS
·
Feb 13

Cathie Wood's Ark Scoops Up $12.4 Million In Beaten-Down Robinhood — Dumps More Airbnb Shares

Benzinga
·
Feb 13

Switzerland's CRISPR Therapeutics misses Q4 revenue expectations

Reuters
·
Feb 13

CRISPR Therapeutics Q4 EPS $(1.37) Misses $(1.09) Estimate, Sales $864.000K

Benzinga
·
Feb 13

IBM, P&G, GameStop, Crispr, AGNC: Insider Moves Exposed

TIPRANKS
·
Jan 31

Cathie Wood’s ARK Investment buys 127K shares of Crispr Therapeutics today

TIPRANKS
·
Jan 30

Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Share Price Movements

Simply Wall St.
·
Jan 29

Top Executive Makes Bold Move With Fresh Crispr Therapeutics AG Stock Buy

TIPRANKS
·
Jan 28

CRISPR Therapeutics AG CFO Prasad Raju Reports Disposal of Common Shares

Reuters
·
Jan 27

CRISPR Therapeutics CEO Samarth Kulkarni Reports Disposal of Common Shares

Reuters
·
Jan 23

BofA Securities Adjusts Price Target on CRISPR Therapeutics AG to $89 From $90, Maintains Buy Rating

MT Newswires Live
·
Jan 22

Is It Time To Reassess CRISPR Therapeutics (CRSP) After Recent Gene Editing Progress?

Simply Wall St.
·
Jan 18